Interleukin-6 and oxidative stress in plasma of alloxan-induced diabetic rabbits after pioglitazone treatment

Immunopharmacology and Immunotoxicology

Volumn 28, Issue 1, 2006, Pages 81-91

  Gumieniczek, A ^a   Hopkala H ^a   Rolinski J ^a   Bojarska Junak, A ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Diabetic Rabbits; Interleukin 6; Oxidative stress; Pioglitazone; Plasma

Indexed keywords

ASCORBIC ACID; GLUCOSE; INTERLEUKIN 6; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; MALE; NONHUMAN; OXIDATIVE STRESS; PLASMA; PRIORITY JOURNAL; PROTEIN CONTENT; RABBIT;

ANIMALS; ASCORBIC ACID; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; HYPOGLYCEMIC AGENTS; INSULIN; INTERLEUKIN-6; MALE; OXIDATIVE STRESS; PROTEINS; RABBITS; THIAZOLIDINEDIONES;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 33646701418     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923970600625785     Document Type: Article

References (32)

1. Esposito, K.; Nappo, F.; Marfella, R.; Giugliano, G.; Giugliano, F.; Ciotola M.; Quagliaro, L.; Ceriello, A., Giugliano, D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans. Role of oxidative stress. Circulation. 2002, 106, 2067-2072.
2. Ogawa, J.; Takahashi, S.; Fujiwara, T.; Fukushige, J.; Hosokawa, T.; Izumi, T.; Kurakata, S.; Horikoshi, H. Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice. Life Sci. 1999, 65, 1287-1296.
3. Pickup, J.C.; Chusney, G.D.; Thomas, S.M.; Burt, D. Plasma interleukin-6, tumor necrosis factor-α and blood cytokine production in type 2 diabetes. Life Sci. 2000, 67, 291-300.
4. Stosic-Grujicic, S.D.; Miljkovic, D.M.; Cvetkovic, I.D.; Maksimovic-Ivanic, D.D.; Trajkovic, V. Immunosuppressive and anti-inflammatory action of antioxidants in rat autoimmune diabetes. J. Autoimmun. 2004, 22, 267-276.
5. Shiomi, T.; Tsutsui. H.; Hayashidani, S.; Suematsu, N.; Ikeuchi, M.; Wen, J.; Ishibashi, M.; Kubota, T.; Egashira, K.; Takeshita, A. Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002, 106, 3126-32.
6. Ghanim, H.; Garg, R.; Aljada, A.; Mohanty, P.; Kumbkarni, Y.; Assian, E.; Hamouda, W.; Dandona, P. Suppression of nuclear factor-κB and stimulation of inhibitor κB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J. Clin. Endocrinol. Metab. 2001, 86, 1306-1312.
7. Aljada, A.; Garg, R.; Ghanim, H.; Mohanty, P.; Hamouda, W.; Assian, E.; Dandona, P. Nuclear factor-κB suppressive and inhibitor-κB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action. J. Clin. Endocrinol. Metab. 2001, 86, 3250-3256.
8. Nattrass, M.; Bailey, C.J. New agents for type 2 diabetes. Baillieres Best Pract. Res. Clin. Endocrinol. Metab. 1999, 13, 309-329.
9. Rahbar, S.; Natarajan, R.; Yerneni, K.; Scott, S.; Gonzales, N.; Nadler, J.L. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin. Chim. Acta 2000, 301, 65-77.
10. Iida, K.T.; Kawakami, Y.; Suzuki, M.; Shimano, H.; Toyoshima, H.; Sone, H.; Shimada, K.; Iwama, Y.; Watanabe, Y.; Mokuno, H.; Kamata, K.; Yamada, N. Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats. Am. J. Physiol. Endocrinol. Metab. 2003, 284, E1125-E1130.
11. Ishida, H.; Takizawa, M.; Ozawa, S.; Nakamichi, Y.; Yamaguchi, S.; Katsuta, H.; Tanaka, T.; Maruyama, M.; Katahira, H.; Yoshimoto, K.; Itagaki, E.; Nagamatsu, S. Pioglitazone improves insulin secretory capacity and prevents the loss of β-cell mass in obese diabetic db/db mice: possible protection of β cell from oxidative stress. Metabolism. 2004, 53, 488-494.
12. Mizushige, K.; Tsuji, T.; Noma, T. Pioglitazone: cardiovascular effects in prediabetic patients. Cardiovasc. Drug Rev. 2002, 20, 329-340.
13. Gumieniczek, A. Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits. Life Sci. 2003, 74, 553-562.
14. Dominguez-Rodriguez, A.; Abreu-Gonzales, P.; Garcia, M.; Ferrer, J.; de la Rosa, A.; Vargas, M.; Reiter, R.J. Light/dark patterns of interleukin-6 in relation to the pineal hormone melatonin in patients with acute myocardial infarction. Cytokine 2004, 26, 89-93.
15. Ito, K.; Shimada, J.; Kato, D.; Toda, S.; Takagi, T.; Naito, Y.; Yoshikawa, T.; Kitamura, N. Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-γ ligand, on lung ischemia-reperfusion in rats. Eur. J. Cardiothorac. Surg. 2004, 25, 530-536.
16. Lowry, O.H.; Rosenbrough, N.J.; Farr, A.L.; Randall, R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275.
17. Kyaw, A. A simple colorimetric method for ascorbic acid determination in blood plasma. Clin. Chim. Acta. 1978, 86, 153-157.
18. Levine, R.L.; Garland, D.; Oliver, C.N.; Amici, A.; Climent, J.; Lenz, A.; Ahn, B.; Shaltiel, S.; Stadtman, E.R. Determination of carbonyl content in oxidatively modified proteins. Methods. Enzymol. 1990; 186, 464-478.
19. Dandona, P.; Aljada, A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. Am. J. Cardiol. 2002, 90, 27G-33G.
20. Dandona, P.; Aljada, A.; Chaudhuri, A. Vascular reactivity and thiazolidinediones. Am. J. Med. 2003, 115, 81S-86S.
21. Yatagai, T.; Nakamura, T.; Nagasaka, S.; Kusaka, I.; Ishikawa, S.; Yoshitaka, A.; Ishibashi, S. Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects. Diabetes Res. Clin. Pract. 2004, 63, 19-26.
22. Pasceri, V.; Wu, H.D.; Willerson, J.T.; Yeh, E.T.H. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation. 2000, 101, 235-238.
23. Ogawa, J.; Takahashi, S.; Fujiwara, T.; Fukushige, J.; Hosokawa, T.; Izumi, T.; Kurakata, S.; Horikoshi, H. Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice. Life Sci. 1999, 65, 1287-1296.
24. Bánhegyi, G.; Braun, L.; Csala, M.; Puskás, F.; Mandl, J. Ascorbate metabolism and its regulation in animals. Free Radic. Biol. Med. 1997, 23, 793-803.
25. Ananthan, R.; Baskar, C.; NarmathaBai, V.; Pari, L.; Latha, M.; Ramkumar, K.M. Antidiabetic effect of Gymnema montanum leaves: effect on lipid peroxidation induced oxidative stress in experimental diabetes. Pharmacol. Res. 2003, 48, 551-556.
26. Škrha, J.; Prázný, M.; Hilgertová, J.; Weiserová, H. Serum α-tocopherol and ascorbic acid concentrations in type 1 and type 2 diabetic patients with and without angiopathy. Clin. Chim. Acta. 2003, 329, 103-108.
27. Telci, A.; Çakatay, U.; Salman, S.; Satman, I.; Sivas, A. Oxidative protein damage in early stage type 1 diabetic patients. Diabetes Res. Clin. Pract. 2000, 50, 213-223.
28. Signorini, A.M.; Fondelli, C.; Renzoni, E.; Puccetti, C.; Gragnoli, G.; Giorgi, G. Antioxidant effects of gliclazide, glibenclamide, and metformin in patients with type 2 diabetes mellitus. Curr. Ther. Res. 2002, 63, 411-420.
29. De Mattia, G.; Laurenti, O.; Fava, D. Diabetic endothelial dysfunction. Effect of free radical scavenging in type 2 diabetic patients. J. Diabetes Complications. 2003, 17, 30-35.
30. Mimič-Oka, J.; Simič, T.; Plješa, M.; Stupar, N.; Turkovič, S. Oxidative modifications of plasma proteins in different stages of chronic renal failure. Facta Universitatis. 2001, 8, 1-5.
31. Martín-Gallan, P.; Carrascosa, A.; Gussinyé, M.; Domínguez, C. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic. Biol. Med. 2003, 34, 1563-1574.
32. Odetti, P.; Garibaldi, S.; Noberasco, G.; Aragno, I.; Valentini, S.; Traverso, N.; Marinari U.M. Levels of carbonyl groups in plasma proteins of type 2 diabetes mellitus. Acta Diabetol. 1999, 36, 179-183.